Sales Growth YoY (Last 12 Months): intensitytherapeutics.com (INTS)

Public company logo of intensitytherapeutics.com (INTS)

Intensity Therapeutics minimizes oncological risks by developing injection methods directly into neoplasms. This chart of trailing 12-month year-over-year revenue growth demonstrates the impact of this strategy, where the metric is recorded at 0.00. Synergy with pharma behemoths and the acquisition of patents support development, although costs for final tests create financial pressure and a dependence on external funding.

Intensity Tx (INTS) Revenue Growth YoY (Last 12 Months): for the period 11/23/2025 - 11/17/2026

Intensity Therapeutics (INTS) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Summary company analytics:Intensity Therapeutics
Product sample of Intensity Tx

Intensity Therapeutics focuses on developing the high-tech DATH platform for targeted oncology therapy. This indicator captures the percentage change in revenue over the last 12 months relative to the same preceding period. The metric allows for an assessment of the commercial scalability of R&D projects and the pace of innovation monetization. A stable trend confirms market demand for the company's developments. By analyzing the relative sales growth over a 12-month period compared to the previous year, an investor determines the stage of business development.

Competitors of Intensity Therapeutics (INTS)

Sales Growth YoY (TTM) NantKwest IBRX|IMCR - Sales Growth YoY (Last Twelve Months)|JANX (januxrx.com) - Sales Growth YoY (Last 12 Months)|Arcus Corp (RCUS) - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Revenue Growth Zymeworks Corp (ZYME)|Revenue Growth YoY (Last 12 Months) TNGX|IOVA - Revenue Growth Rate YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) IMTX (Immatics Corp)|Revenue Change YoY (Last 12 Months) XNCR|Sales Growth YoY (TTM) CMPX (Compass Therapeutics, Inc.)|Revenue Dynamics YoY (Last Twelve Months) REPL|lyell.com - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Innate Pharma S.A|Pyxis (PYXS) - Sales Growth YoY (Last Twelve Months)|Compugen Ltd - Revenue Dynamics YoY (Last Twelve Months)|IOBT (iobiotech.com) - Sales Growth YoY (TTM)|Sales Growth YoY (TTM) Sutro Biopharma Inc.|Sales Growth YoY (Last Twelve Months) MiNK Therapeutics (INKT)|HOWL: Trailing Twelve Months Sales Growth|Immix Biopharma - Revenue Growth YoY (Last 12 Months)|ALX Oncology (ALXO) - Trailing Twelve Months Revenue Growth|CUE: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Sales Growth PDSB|sonnetbio.com (SONN) - Sales Growth YoY (Last Twelve Months)|MAIA Biotechnology Inc (MAIA) - Sales Growth YoY (TTM)|Sales Growth YoY (Last Twelve Months) liminatuspharma.com|Sales Growth YoY (Last Twelve Months) LVTX|Revenue Growth YoY (Last 12 Months) NXTC (NextCure, Inc.)|LPTX: Trailing Twelve Months Sales Growth|Sales Growth YoY (TTM) SNSE (Sensei Biotherapeutics, Inc.)|Annual Revenue Growth (Last Twelve Months) Theriva Biologics, Inc. (TOVX)|GRTS: Revenue Growth YoY (Last 12 Months)|Annual Revenue Growth (Last Twelve Months) kinetabio.com KA|NEXI (neximmune.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth Turnstone Biologics Corporation (TSBX)|Revenue Growth YoY (Last 12 Months) VCNX|HARP: Revenue Dynamics YoY (Last Twelve Months)